Looking to score the best deal on your next game ticket? A new Houston-founded app promises to revolutionize the resale market. Photo via Getty Images

Online platforms have long simplified the process of buying, selling, and trading event tickets. But what happens when your tickets don’t sell or when you’re stuck with costly season tickets you can’t use? You might end up giving them away or leaving them unused, leading to a financial loss either way.

This is the challenge that Houstonian Jerin Varkey is willing to address with Offer Approved, a new platform that empowers sellers and buyers, guaranteeing that no seat goes unused.

The idea took root around two years ago when Varkey, a passionate sports fan and season ticket holder, faced a new challenge. After becoming a parent, he found himself unable to attend every game. Frustrated with traditional resale platforms, he quickly realized that high fees and limited time made it difficult to sell all his tickets, causing him to lose money each time.

"I knew there was someone out there willing to pay $50," he recalls.

A transparent market for resale tickets


Offer Approved is a transparent and trusted platform for both sellers and buyers. Screenshots courtesy of Offer Approved

With this idea in mind, he started intensive research through 2023, identifying the multiple inefficiencies in the ticket market, including seeing the same seat in different marketplaces simultaneously.

“You’ll go through the checkout process and discover that those seats are no longer available; what happens is somebody bought it a few seconds before you on a different site, and the new system is taking it down," Varkey tells InnovationMap.

Scams, falsification, and security flaws were also among the problems. Offer Approved aims to fix these gaps by offering a transparent and trusted platform for both sellers and buyers, specifically to season ticket holders who leave several seats empty at stadiums each night.

“Sellers now have better visibility into the market, and we assist them in managing their listings," Varkey explains. "If a ticket is listed at $100, the seller can set a hidden minimum price of $80 or $70. Any offer that meets or exceeds that amount is automatically accepted, saving them the hassle of manually adjusting prices each time.”

A business model focused on sustainable growth

Varkey initially partnered with angel investors to bring the developer and a technical team. He prefers to avoid paid advertising, opting instead for a more sustainable business approach, including a small fee for sellers and a service charge for managing season tickets.

The project is currently self-funded, and Varkey is focused on ensuring long-term sustainability.

"I'm perfectly fine with taking things slowly. My priority is to make sure the model is sound first," he says.

Offer Approved is currently seeking season ticket holders and partnerships to build supply. He has also been in conversations with Toyota Center, NRG Stadium, and Minute Maid Park and their sports teams.

From corporate worker to visionary founder

Jerin Varkey founded Offer Approved to target unsold resale tickets to sporting events. Photo courtesy of Offer Approved

Varkey’s entrepreneurial journey started in the corporate world at Shell where he worked for ten years within capital project management and business improvement.

“It was a great experience, and I learned a lot, but I constantly felt the urge to say, 'This could be improved if we made some changes.' That kind of flexibility just wasn't possible in large corporate environments,” he recalls.

Varkey says he always tried to build innovative projects on the side until he finally left the company in 2018 and started working for venture-backed startups, where he found a space to bring his ideas to life.

For the past five years, Varkey has worked for startups like Gympass and Entera as a head of strategy and analytics. Now, as the founder of Offer Approved, he continues to work on new projects while driving his ticketing platform forward in Houston.

Varkey’s vision goes beyond just sports tickets and local markets — he aims to expand into areas like restaurant reservations, hotel stays, and other time-sensitive services, even offering deals to clients when traveling or exploring new cities.

“I believe in the power of negotiation, and I envision a future where people can make offers on anything with an expiration date,” he says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.